^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Dabrafenib plus trametinib is recommended (category 2A; preferred) for patients with BRAF V600E mutations. If combination therapy with dabrafenib/trametinib is not tolerated, single-agent therapy with dabrafenib or vemurafenib are "other recommended" agents.
Source:
Title:
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
...patients with advanced BRAF-mutant lung cancer received treatment with either vemurafenib (n=29), dabrafenib (n=9) or sorafenib (n=1). Of the BRAF mutations, 83% were BRAF V600E. The ORR was 53% and the PFS and OS were 5 and 10.8 months, respectively.
DOI:
Ann Oncol (2018) 29 (suppl 4): iv192–iv237
Excerpt:
ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Source:
Title:
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
Excerpt:
...At baseline, genetic testing reports of BRAF V600E mutation can be provided; 4....
Trial ID:
Source:
Title:
Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer (NSCLC).
Published date:
05/28/2020
Excerpt:
Of 30 V600E-mutated patients who received anti-BRAF therapy during the course of disease, the median PFS of vemurafenib, dabrafenib, and dabrafenib plus trametinib was 7.8 months, 5.8 months and 6.0 months, respectively (P = 0.970)….Our data demonstrated the clinical benefit of anti-BRAF targeted therapy in Chinese NSCLC patients harboring BRAF-V600E mutation.
DOI:
10.1200/JCO.2020.38.15_suppl.e21745
Source:
Title:
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Excerpt:
In the 24 evaluable patients with BRAF V600E and vemurafenib therapy, ORR was 54% (95% CI: 32.8–74.4) and DCR was 96% (95% CI: 78.9–99.9). Among the five patients with first-line vemurafenib therapy, three (60%) had a response.
DOI:
10.1097/JTO.0000000000000625
Source:
Title:
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
Excerpt:
Patients with BRAF mutations are administered vemurafenib...Fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1), composing the largest tumor-pathway cohort in the BRAF group (Table 4). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days (Fig 2D). The median DOR was 5 months (range, 4 to 14 months).
DOI:
10.1200/JCO.2017.75.3780
Trial ID:
Source:
Title:
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
Excerpt:
Our patient's visceral disease improved supporting vemurafenib's efficacy in the treatment of metastatic BRAF-mutated NSCLC.
DOI:
10.1016/j.lungcan.2014.05.009
Source:
Title:
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Excerpt:
...molecular analyses were performed and revealed a BRAF V600E mutation....Off-label vemurafenib was started in September 2012 at a dose of 960 mg administered twice per day....PET/CT scanning in October 2012 after 6 weeks of treatment showed complete response, with no residual metabolic activity in the hepatic lesions.
DOI:
10.1200/JCO.2012.47.6143.
